Gamma-Amino Butyric Acid (GABA) Deficits and Vulnerability to Cannabinoid-Induced Psychosis

Yale University1 个研究点分布在 1 个国家目标入组 17 人开始时间: 2009年2月11日最近更新: 2022年12月5日

适应症

干预措施

试验速览

阶段: 早期 1 期
状态: 已完成
发起方: Yale University
入组人数: 17
试验地点: 1
主要终点: Clinician Administered Dissociative Symptoms Scale

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The study aims to examine the combined effects of delta-9-tetrahydrocannabinol (∆-9-THC or THC) and iomazenil on thinking, perception, mood, memory, attention, and electrical activity of the brain (EEG). THC is the active ingredient of marijuana, cannabis, "ganja", or "pot". Iomazenil is a drug that works opposite to drugs like valium. The purpose of this study is to determine whether the administration of iomazenil will alter the effects of THC.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Crossover
主要目的: Basic Science
盲法: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围: 18 Years 至 55 Years（Adult）
性别: Male
接受健康志愿者: 是

入选标准

•Exposed to cannabis at least once in their lifetime

排除标准

•Cannabis naïve
•History of hearing deficit

研究组 & 干预措施

THC and Iomazenil

Active Comparator

Iomazenil: 3.7 μg/kg intravenously over 10 minutes
Delta-9-THC (0.015 mg/kg = 1.05 mg in a 70kg individual), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or "joint". It is administered intravenously for 10 minutes

干预措施: THC and Iomazenil (Drug)

Placebo

Placebo Comparator

Control: small amount of alcohol intravenous (quarter teaspoon), with no THC

干预措施: Placebo (control) (Drug)